Formations en Cancérologie, Formations Continue - Institut ...

November 5, 2010 triyonohadi Leave a comment Go to comments. S. Camporesi . For the first time, was organized the meeting in winter 2009 Pharmacology and molecular mechanisms (PAMM) in connection with the EGAM (EORTC group Meeting) in Brussels.Furthermore, the PAMM participated in an additional plenary session together with the Pathobiology, group (PBG) and the functional imaging Group during ... EORTC Cancer Research Fund. EBCC 12. EBCC 12 is now an On Demand Conference! If you did not have time to register and participate in EBCC 12 Conference, you can still register and view all the sessions! 32nd EORTC-NCI-AACR Symposium. View the conference. Innovation and Biomarkers in Cancer Drug Development (IBCD) View the conference. Activities. Clinical trials; Other research initiatives ... EORTC 24891: Overall Survival (years) 0 2 4 6 8 10 12 14 16 0 10 20 30 40 50 60 70 80 90 100 O N Number of patients at risk : Treatment 81 94 49 36 26 14 9 5 3 83 100 62 47 27 17 8 4 1 Surgery PF Induction Chemotherapy Hazard Ratio: 0.88 (95% CI: 0.65 - 1.19) P-value for non-inferiority of PF: P=0.0015 Surgery Lefebvre, Presented 2007 EORTC PAMM GROUP Meeting From the 27th to 30th january 2010 OBJECTIVES The 31st Annual EORTC-PAMM Group Meeting will be held 28 - 30 January 2010 in Toulouse, France. The main topic of the meeting will be "Treatment Individualization" and will focus on the different groups of anticancer agents, i.e., drugs interacting with DNA, tyrosine kinases, hormonal receptors, checkpoints, and inhibitors ... The 31st Annual EORTC-PAMM Group Meeting will be held 28 – 30 January 2010 in Toulouse, France. The main topic of the meeting will be “Treatment Individualization” and will focus on the different groups of anticancer agents, i.e., drugs interacting with DNA, tyrosine kinases, hormonal receptors, checkpoints, and inhibitors of angiogenesis.

[index] [1835] [14555] [2980] [13464] [6840] [3539] [3386] [7356] [316] [13092]

#

test2